Jan Kervitzer
6 Papers
6 Citations
Jan Kervitzer is an academic researcher. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Internal medicine. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
Monika Zurkova,Eva Kriegova,Vitezslav Kolek,Vladimira Lostakova,Martina Sterclova,Vladimir Bartos,Martina Doubková,Ilona Binková,Michal Svoboda,Jana Strenková,Marketa Janotova,Martina Plačková,Ladislav Lacina,Vladimir Rihak,Frantisek Petrik,Pavlína Lisá,Radka Bittenglova,Richard Tyl,Gustav Ondrejka,Hana Suldova,Jaroslav Lnenicka,Jana Psikalova,Tomas Snizek,Jiri Homolka,Renata Králová,Jan Kervitzer,Martina Vasakova +26 more
TL;DR: The 2-yrs sustained effect of pirfenidone on the decline of lung function and survival in the real-world patient’s IPF cohort is observed and DLCO decline of ≥10% shows a potential as a mortality predictor in IPF patients on pirfenodone, and should be routinely evaluated during follow-up examinations.
104
Does timeliness of diagnosis influence survival and treatment response in idiopathic pulmonary fibrosis? Real- world results from the EMPIRE registry
Martina Vasakova,Nesrin Mogulkoc,Martina Sterclova,Beata Zolnowska,Vladimir Bartos,Martina Plačková,Veronika Müller,Ladislav Lacina,Robert Slivka,Martina Doubková,Marina Roksandic Milenkovic,Radka Bittenglova,Imrich Jonner,Magdalena Martusewicz-Boros,Monika Žurková,Ilona Binková,Małgorzata Sobiecka,Richard Tyl,Marzena Trzaska-Sobczak,Pawel Sliwinski,Vladimíra Lošťáková,Sebastian Majewski,Pavlína Lisá,Katarzyna Lewandowska,Hana Suldova,Jasna Tekavec-Trkanjec,Amelia Szymanowska-Narloch,Lenka Šišková,Anikó Bohács,Ján Plutinský,Bohumil Matula,Štefan Tóth,František Petřík,Margita Bučeková,Jana Psikalova,Miklós Zsiray,Jaroslav Lněnička,Vladimír Řihák,Zsuzsanna Szalai,Zoltán Balikó,Štefan Laššán,Pavlina Musilova,Imre Lajkó,Tomáš Snížek,Jan Anton,Jiří Homolka,Peter Paluch,Robert Vyšehradský,Renata Králová,Jan Kervitzer,Daniel Doležal,Mária Szilasi,Jan Kus,Dragana Jovanovic,Marta Hájková,Michal Svoboda,Jana Strenková +56 more
TL;DR: The patients with IPF diagnosed within 1 year from symptoms have longer survival than those diagnosed later and treatment with antifibrotic drugs similarly reduced decline of VC and TLCO in both early and later diagnosed patients.
8
Analysis of comorbid conditions in 1210 IPF patients from the EMPIRE registry
D. Jovanovic,Nesrin Mogulkoc,Martina Sterclova,Beata Zolnowska,Vladimir Bartos,Martina Plačková,Veronika Müller,Ladislav Lacina,Robert Slivka,Martina Doubková,Marina Roksandic Milenkovic,Radka Bittenglova,Imrich Jonner,Magdalena Martusewicz-Boros,Monika Žurková,Ilona Binková,Małgorzata Sobiecka,Richard Tyl,Marzena Trzaska-Sobczak,Pawel Sliwinski,Vladimíra Lošťáková,Sebastian Majewski,Pavlína Lisá,Katarzyna Lewandowska,Hana Suldova,Jasna Tekavec-Trkanjec,Amelia Szymanowska-Narloch,Lenka Šišková,Anikó Bohács,Ján Plutinský,Bohumil Matula,Štefan Tóth,František Petřík,Margita Bučeková,Jana Psikalova,Miklós Zsiray,Jaroslav Lněnička,Vladimír Řihák,Zsuzsanna Szalai,Zoltán Balikó,Štefan Laššán,Pavlina Musilova,Imre Lajkó,Tomáš Snížek,Jan Anton,Jiří Homolka,Peter Paluch,Robert Vyšehradský,Renata Králová,Jan Kervitzer,Daniel Doležal,Mária Szilasi,Jan Kus,Marta Hájková,Michal Svoboda,Jana Strenková,Martina Vasakova +56 more
TL;DR: Management of IPF requires a comprehensive approach, which includes the identification and treatment of comorbid conditions to optimize patient outcomes, and the prevalence of COPD, sleep breathing disorder, asthma, nephropathy, hyperlipidaemia, prostatic hypertrophy and depression was strikingly lower than in GP.
3
Does early diagnosis of idiopathic pulmonary fibrosis matter?Real-world's data from the EMPIRE registry
Martina Vasakova,Martina Sterclova,Jan Kus,Vladimir Bartos,Marta Hájková,Martina Doubková,Veronika Müller,Martina Plačková,Monika Zurkova,Vladimira Lostakova,Ladislav Lacina,Vladimir Rihak,Frantisek Petrik,Pavlína Lisá,Radka Bittenglova,Dragana Jovanovic,Richard Tyl,Gustav Ondrejka,Hana Suldova,Jaroslav Lnenicka,Jana Psikalova,Tomas Snizek,Jiri Homolka,Renata Králová,Jan Kervitzer,Michal Svoboda,Jana Strenková +26 more
TL;DR: The results show that earlier diagnosis and treatment may increase survival in IPF, and maximal effort should be generated to get the patients diagnosed and treated as early as possible.
2
The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Monika Zurkova,Vitezslav Kolek,Vladimira Lostakova,Eva Kriegova,Martina Sterclova,Vladimir Bartos,Martina Doubková,Ilona Binková,Michal Svoboda,Jana Strenková,Martina Plačková,Ladislav Lacina,Vladimir Rihak,Frantisek Petrik,Pavlína Lisá,Radka Bittenglova,Richard Tyl,Gustav Ondrejka,Hana Suldova,Jaroslav Lnenicka,Jana Psikalova,Tomas Snizek,Jiri Homolka,Renata Králová,Jan Kervitzer,Martina Vasakova +25 more
TL;DR: In Czech IPF patients, pirfenidone administration was associated with the lower decrease in lung function (FVC, TLCO) comparing with other treatment modalities, and this observation supports current recommendation of pirferidon for mild and moderate IPF.
1